首页> 外文期刊>Trials >PALLiON – PALLiative care Integrated in ONcology: study protocol for a Norwegian national cluster-randomized control trial with a complex intervention of early integration of palliative care
【24h】

PALLiON – PALLiative care Integrated in ONcology: study protocol for a Norwegian national cluster-randomized control trial with a complex intervention of early integration of palliative care

机译:Pallion - 姑息地区核心护理:挪威国家集群随机控制试验的研究议定书,其早期融入姑息治疗

获取原文
       

摘要

BACKGROUND:Several publications have addressed the need for a systematic integration of oncological care focused on the tumor and palliative care (PC) focused on the patient with cancer. The exponential increase in anticancer treatments and the high number of patients living longer with advanced disease have accentuated this. Internationally, there is now a persuasive argument that introducing PC early during anticancer treatment in patients with advanced disease has beneficial effects on symptoms, psychological distress, and survival.METHODS:This is a national cluster-randomized trial (C-RCT) in 12 Norwegian hospitals. The trial investigates effects of early, systematic integration of oncology and specialized PC in patients with advanced cancer in six intervention hospitals compared with conventional care in six. Hospitals are stratified on the size of local catchment areas before randomization. In the intervention hospitals, a three-part complex intervention will be implemented. The backbone of the intervention is the development and implementation of patient-centered care pathways that contain early, compulsory referral to PC and regular and systematic registrations of symptoms. An educational program must be completed before patient inclusion. A total of 680 patients with advanced cancer and one caregiver per patient are included when patients come for start of last line of chemotherapy, defined according to national treatment guidelines. Data registration, clinical variables, and patient- and caregiver-reported outcomes take place every 2 months for 1 year or until death. The primary outcome is use of chemotherapy in the last 3 months of life by comparing the proportion of patients who receive this in the intervention and control groups. Primary outcome is use of chemotherapy in the last 3 months before death, i.e. number of patients. Secondary outcomes are initiation, discontinuation and number of cycles, last 3 months of life, administration of other medical interventions in the last month of life, symptom burden, quality of life (QoL), satisfaction with information and follow-up, and caregiver health, QoL, and satisfaction with care.DISCUSSION:Results from this C-RCT will be used to raise the awareness about the positive outcomes of early provision of specialized palliative care using pathways for patients with advanced cancer receiving medical anticancer treatment. The long-term clinical objective is to integrate these patient-centered pathways in Norwegian cancer care. The specific focus on the patient and family and the organization of a predictable care trajectory is consistent with current Norwegian strategies for cancer care.TRIAL REGISTRATION:ClinicalTrials.gov, NCT03088202. Registered on 23 March 2017.
机译:背景:若干出版物已经解决了需要系统地整合肿瘤护理,其专注于肿瘤和姑息治疗(PC),其专注于患有癌症的患者。抗癌治疗的指数增加和患有晚期疾病的大量患者的患者突出了这一点。在国际上,现在有一个有说服力的论据,即早期疾病患者抗癌治疗早期引入PC对症状,心理困扰和生存有益的作用。方法:这是12个挪威的全国性随机试验(C-RCT)医院。试验研究了六个干预医院中晚期癌症患者的早期,系统整合的肿瘤和专用PC的影响与六个术语相比。在随机化之前,医院的分层是局部集水区的大小。在干预医院中,将实施三部分的复杂干预。干预的骨干是开发和实施患者中心护理途径,其含有早期,强制转诊到PC以及症状的定期和系统注册。必须在患者包容之前完成教育计划。每位患者共有680例先进的癌症和一个护理人员,当患者开始时,患者开始于上一系列化疗,根据国家治疗指南定义。数据登记,临床变量和患者和护理人员报告的结果每2个月持续1年或直到死亡。通过比较在干预和对照组中获得这一点的患者的比例来使用化疗在过去3个月内使用化疗。主要结果是在死亡前3个月内使用化疗,即患者数量。二次结果是启动,停止和周期数,最后3个月的生命,在最后一个月的生命中给予其他医疗干预措施,症状负担,生活质量(QOL),与信息和后续行动的满意度,以及照顾者健康,QoL和CareSion的满意度。探讨:这一C-RCT的结果将用于提高对早期提供专业姑息治疗的积极结果的认识,使用治疗医疗抗癌治疗的晚期癌症患者的途径。长期临床目的是将这些以核心癌症护理的这些患者为中心的途径整合。具体关注患者和家庭以及可预测的护理轨迹的组织与目前的挪威癌症护理策略一致.Tirial注册:ClinicalTrials.gov,NCT03088202。 2017年3月23日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号